Journal articleClin Transl Oncol2024
Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
- Journal
- Clin Transl Oncol
- Published
- 4 October 2023
- Citations
- 2
- Type
- Article
- License
- cc by
- Full text
- Open access, reuse-licensed (cc by)
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Its licensed text is not loaded here yet, so most questions will be declined.
Try
Trials 3
- Builds on itAfatinib as Cancer Therapy for Exocrine Pancreatic Tumours NCT01728818↗
- Builds on itGemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer NCT01729481↗
- Builds on itCapecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine NCT00440167↗